Exceptionally rapid response to pembrolizumab in a SMARCA4‐deficient thoracic sarcoma overexpressing PD‐L1: A case report

SMARCA4‐deficient thoracic sarcoma (SMARCA4‐DTS) is a new clinical entity characterized by SMARCA4 inactivation and has a dismal prognosis because of rapid growth. Effective treatments for SMARCA4‐DTS have not yet been developed. Most recently, anti‐programmed cell death 1 receptor (PD‐1) blockade h...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Thorac Cancer
Päätekijät: Takada, Kohichi, Sugita, Shintaro, Murase, Kazuyuki, Kikuchi, Tomoki, Oomori, Ginji, Ito, Ryo, Hayasaka, Naotaka, Miyanishi, Koji, Iyama, Satoshi, Ikeda, Hiroshi, Kobune, Masayoshi, Emori, Makoto, Kato, Junji, Hasegawa, Tadashi
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley & Sons Australia, Ltd 2019
Aiheet:
Case Reports
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6885443/
https://ncbi.nlm.nih.gov/pubmed/31617320
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13215
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia